NASDAQ:NBRV

Nabriva Therapeutics Competitors

$1.47

+0.02 (+1.38 %)

(As of 04/14/2021 03:01 PM ET)

Add

Compare

Today's Range

$1.44

Now: $1.47▼

$1.54

50-Day Range

$1.56

MA: $1.90▼

$2.80

52-Week Range

$1.42

Now: $1.47▼

$12.00

Volume20,195 shs

Average Volume2.10 million shs

Market Capitalization$367.86 million

P/E RatioN/A

Dividend YieldN/A

Beta1.91

Nabriva Therapeutics (NASDAQ:NBRV) Vs. SAVA, AMTI, GBIO, ZEAL, ATBPD, and ENDP

Should you be buying NBRV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Nabriva Therapeutics, including Cassava Sciences (SAVA), Applied Molecular Transport (AMTI), Generation Bio (GBIO), Zealand Pharma A/S (ZEAL), Antibe Therapeutics (ATBPD), and Endo International (ENDP).

Nabriva Therapeutics vs. Cassava Sciences Stock

Cassava Sciences (NASDAQ:SAVA) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Cassava Sciences and Nabriva Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-22.01%	-20.85%
Nabriva Therapeutics	-1,682.55%	-129.80%	-71.67%

Analyst Ratings

This is a summary of current recommendations for Cassava Sciences and Nabriva Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	0	0	4	0	3.00
Nabriva Therapeutics	0	1	1	0	2.50

Cassava Sciences currently has a consensus target price of $35.3333, indicating a potential downside of 1.99%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Cassava Sciences.

Institutional and Insider Ownership

26.7% of Cassava Sciences shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 13.7% of Cassava Sciences shares are owned by company insiders. Comparatively, 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cassava Sciences and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	$-4,630,000.00	($0.27)	-131.26
Nabriva Therapeutics	$9.48 million	38.80	$-82,760,000.00	($11.20)	-0.13

Cassava Sciences has higher earnings, but lower revenue than Nabriva Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cassava Sciences has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

Summary

Cassava Sciences beats Nabriva Therapeutics on 9 of the 13 factors compared between the two stocks.

Nabriva Therapeutics vs. Applied Molecular Transport Stock

Applied Molecular Transport (NASDAQ:AMTI) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Applied Molecular Transport and Nabriva Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Molecular Transport	N/A	N/A	N/A
Nabriva Therapeutics	-1,682.55%	-129.80%	-71.67%

Analyst Ratings

This is a summary of current recommendations for Applied Molecular Transport and Nabriva Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Molecular Transport	0	0	4	0	3.00
Nabriva Therapeutics	0	1	1	0	2.50

Applied Molecular Transport currently has a consensus target price of $68.75, indicating a potential upside of 62.61%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Applied Molecular Transport.

Institutional and Insider Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Molecular Transport and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Molecular Transport	N/A	N/A	$-28,040,000.00	N/A	N/A
Nabriva Therapeutics	$9.48 million	38.80	$-82,760,000.00	($11.20)	-0.13

Applied Molecular Transport has higher earnings, but lower revenue than Nabriva Therapeutics.

Summary

Applied Molecular Transport beats Nabriva Therapeutics on 7 of the 10 factors compared between the two stocks.

Nabriva Therapeutics vs. Generation Bio Stock

Generation Bio (NASDAQ:GBIO) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Generation Bio and Nabriva Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generation Bio	N/A	N/A	N/A
Nabriva Therapeutics	-1,682.55%	-129.80%	-71.67%

Analyst Ratings

This is a summary of current recommendations for Generation Bio and Nabriva Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generation Bio	0	0	6	0	3.00
Nabriva Therapeutics	0	1	1	0	2.50

Generation Bio currently has a consensus target price of $40.60, indicating a potential upside of 52.46%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Generation Bio.

Institutional and Insider Ownership

63.3% of Generation Bio shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Generation Bio and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generation Bio	N/A	N/A	N/A	N/A	N/A
Nabriva Therapeutics	$9.48 million	38.80	$-82,760,000.00	($11.20)	-0.13

Generation Bio has higher earnings, but lower revenue than Nabriva Therapeutics.

Summary

Generation Bio beats Nabriva Therapeutics on 6 of the 9 factors compared between the two stocks.

Nabriva Therapeutics vs. Zealand Pharma A/S Stock

Zealand Pharma A/S (NASDAQ:ZEAL) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Zealand Pharma A/S and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$6.20 million	229.53	$-85,670,000.00	($2.54)	-12.91
Nabriva Therapeutics	$9.48 million	38.80	$-82,760,000.00	($11.20)	-0.13

Nabriva Therapeutics has higher revenue and earnings than Zealand Pharma A/S. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.3% of Zealand Pharma A/S shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zealand Pharma A/S and Nabriva Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	-214.31%	-38.34%	-30.40%
Nabriva Therapeutics	-1,682.55%	-129.80%	-71.67%

Analyst Ratings

This is a summary of current recommendations for Zealand Pharma A/S and Nabriva Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	0	2	0	3.00
Nabriva Therapeutics	0	1	1	0	2.50

Zealand Pharma A/S currently has a consensus target price of $43.00, indicating a potential upside of 31.14%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Zealand Pharma A/S.

Risk & Volatility

Zealand Pharma A/S has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

Nabriva Therapeutics vs. Antibe Therapeutics Stock

Antibe Therapeutics (NASDAQ:ATBPD) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Antibe Therapeutics and Nabriva Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	$7.51 million	188.60	$-14,540,000.00	($0.50)	-7.32
Nabriva Therapeutics	$9.48 million	38.80	$-82,760,000.00	($11.20)	-0.13

Antibe Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Antibe Therapeutics and Nabriva Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	-273.96%	-176.23%	-106.91%
Nabriva Therapeutics	-1,682.55%	-129.80%	-71.67%

Analyst Recommendations

This is a breakdown of recent ratings for Antibe Therapeutics and Nabriva Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0	0	0	0	N/A
Nabriva Therapeutics	0	1	1	0	2.50

Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Antibe Therapeutics.

Volatility and Risk

Antibe Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Summary

Nabriva Therapeutics beats Antibe Therapeutics on 9 of the 13 factors compared between the two stocks.

Nabriva Therapeutics vs. Endo International Stock

Endo International (NASDAQ:ENDP) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Endo International and Nabriva Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endo International	$2.91 billion	0.49	$-422,640,000.00	$2.38	2.61
Nabriva Therapeutics	$9.48 million	38.80	$-82,760,000.00	($11.20)	-0.13

Nabriva Therapeutics has lower revenue, but higher earnings than Endo International. Nabriva Therapeutics is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.0% of Endo International shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Comparatively, 2.8% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Endo International and Nabriva Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endo International	-5.30%	-85.80%	7.19%
Nabriva Therapeutics	-1,682.55%	-129.80%	-71.67%

Analyst Recommendations

This is a breakdown of recent ratings for Endo International and Nabriva Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endo International	2	3	3	0	2.13
Nabriva Therapeutics	0	1	1	0	2.50

Endo International presently has a consensus target price of $7.6667, indicating a potential upside of 22.47%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Endo International.

Volatility and Risk

Endo International has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.